Adult Congenital Heart Disease Registry (QuERI)

Actelion Pharmaceuticals

Status: Completed

Conditions: Pulmonary Arterial Hypertension

Treatments: Other: Observational

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01659411

AC-052-433

CHRC2011-ACHD001 (Other Identifier)

Details and patient eligibility

About

Multi-center, observational, U.S.-based longitudinal program. Data will be collected prospectively for 3 years. Individual physician feedback will be provided on data collected with the purpose of improving the management of patients - quality enhancement research initiative (QuERI) process from adult patients enrolled with a history of repaired Congenital Heart Disease (CHD).

Full description

Approximately 800 male and female adult patients with a history of repaired CHD will be recruited from approximately 100 cardiology practices and will be followed up every twelve months for the period of three years. Consecutive patients in each practice meeting inclusion and exclusion criteria should be considered for the study. Two groups of subjects will be enrolled based on identical exclusion criteria and inclusion criteria, with the exception only of inclusion criteria #3: cohort 1- those demonstrating historic high risk criteria and cohort 2 - those demonstrating current high risk criteria.

Enrollment: 217 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Cohort 1 (historic high risk)

1. Male and female adults (≥ 18 years of age)

2. Patients with documented history (at least one year) of an isolated, repaired congenital heart defect such as ASD, VSD, PDA, AVC (AVSD)

3. History of a large defect prior to closure as evidenced by any one of the following:

   • Size of: ASD > 2 cm; VSD > 1 cm; PDA > 0.6 cm
   • Shunt 2:1 or greater
   • Pre-operative PH (PAS > 40 mmHg) or documented shunt- related heart failure (radiographic evidence)
   • Pre-operative atrial fibrillation or flutter

4. High risk features (any one the following):

   • Age > 40 years

   • Later surgical repair:

     i. ≥ 2 years of age for PDA or VSD ii. ≥ 1 year of age for AVC iii. ≥ 10 years of age for ASD

   • Sinus venosus defect

   • Primum defect

   • WHO functional class > 1

   • Atrial fibrillation or flutter

5. Echocardiographic evidence of high risk features. Any one of the following:

   • Degree of TR that is mild or greater

   • Right ventricular (RV) systolic dysfunction

   • Evidence of RV dilatation: Any one of the following:

     i. Evidence of RV dilation by general, qualitative assessment ii. RV end diastolic diameter > 3.2 cm on apical 4 chamber view at the tips of the tricuspid valve iii. RV to LV ratio at end-diastole > 0.6 (RV and LV end diastolic dimensions measured from apical 4 chamber view, 1 cm apical of the respective valve annuli)

   • Any abnormality in the motion of the inter-ventricular septum

6. Ability and desire to execute the consent for follow up

Inclusion Criteria: Cohort 2 (current high risk)

1. Male and female adults (≥ 18 years of age)

2. Patients with documented history (at least one year) of an isolated, repaired congenital heart defect such as ASD, VSD, PDA, AVC (AVSD)

3. Current (within the last 12 months) evidence of 1 or more of the 7 following criteria:

   • Desaturation on exercise (92% or less)
   • 6 MWD <380 m
   • PFT demonstrating DLC <70% predicted & FEV1>70% predicted
   • ECG demonstrating i) RAD and ii) RVH or RAE
   • Physical findings of edema accompanied by elevated JVP and +HJR
   • CXR evidence of enlarged main and/or hilar pulmonary arterial shadows in association with right ventricular enlargement
   • Elevated biomarks (BNP or NT-proBNP above upper limit of normal)

4. High risk features (any one of the following:)

   • Age > 40 years

   • Later surgical repair:

     i. ≥ 2 years of age for PDA or VSD ii. ≥ 1 year of age for AVC iii. ≥ 10 years of age for ASD

   • Sinus venosus defect

   • Primum defect

   • WHO functional class > 1

   • Atrial fibrillation or flutter

5. Echocardiographic evidence of high risk features. Any one of the following:

   • Degree of TR that is mild or greater

   • Right ventricular (RV) systolic dysfunction

   • Evidence of RV dilatation: Any one of the following:

     i. Evidence of RV dilation by general, qualitative assessment ii. RV end diastolic diameter > 3.2 cm on apical 4 chamber view at the tips of the tricuspid valve iii. RV to LV ratio at end-diastole > 0.6 (RV and LV end diastolic dimensions measured from apical 4 chamber view, 1 cm apical of the respective valve annuli)

   • Any abnormality in the motion of the inter-ventricular septum

6. Ability and desire to execute the consent for follow up

Exclusion Criteria:

1. Poor mental function, drug or substance (e.g., alcohol) abuse, or unstable psychiatric illness, which, in the opinion of the investigator, may interfere with optimal participation in the study
2. Diagnosis of PAH (defined as RHC demonstrating mPAP ≥ 25 mm Hg and PCWP ≤ 15 and PVR > 3 WU or PVR (indexed) > 4 WU or treatment with PAH specific therapy) after surgical repair and prior to visit 1
3. Prior inclusion in this registry

Trial design

217 participants in 1 patient group

Adult CHD Patients

Description:

observational

Treatment:

Other: Observational